These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 36536128)

  • 1. Daily briefing: Vaccines and treatments are coming for RSV.
    Graham F
    Nature; 2022 Dec; ():. PubMed ID: 36536128
    [No Abstract]   [Full Text] [Related]  

  • 2. RSV wave hammers hospitals - but vaccines and treatments are coming.
    Fairbank R
    Nature; 2022 Dec; ():. PubMed ID: 36522537
    [No Abstract]   [Full Text] [Related]  

  • 3. Daily briefing: US children's hospitals swamped by RSV.
    Graham F
    Nature; 2022 Nov; ():. PubMed ID: 36329141
    [No Abstract]   [Full Text] [Related]  

  • 4. Daily briefing: mRNA vaccine for RSV shows promise.
    Graham F
    Nature; 2023 Jan; ():. PubMed ID: 36658354
    [No Abstract]   [Full Text] [Related]  

  • 5. Daily briefing: World's first vaccine for RSV approved.
    Graham F
    Nature; 2023 May; ():. PubMed ID: 37147365
    [No Abstract]   [Full Text] [Related]  

  • 6. RSV: A vaccine is coming, time to educate providers.
    Ciemins EL; Gillen A; Tallam M
    Vaccine; 2023 Jul; 41(32):4636-4638. PubMed ID: 37328353
    [No Abstract]   [Full Text] [Related]  

  • 7. Development of bioluminescence imaging of respiratory syncytial virus (RSV) in virus-infected live mice and its use for evaluation of therapeutics and vaccines.
    Fuentes S; Arenas D; Moore MM; Golding H; Khurana S
    Vaccine; 2017 Jan; 35(4):694-702. PubMed ID: 27989627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daily briefing: A supernova is coming - and astronomers are ready.
    Graham F
    Nature; 2022 Feb; ():. PubMed ID: 35194218
    [No Abstract]   [Full Text] [Related]  

  • 9. Respiratory syncytial virus in adults with comorbidities: an update on epidemiology, vaccines, and treatments.
    Bouzid D; Visseaux B; Ferré VM; Peiffer-Smadja N; Le Hingrat Q; Loubet P
    Clin Microbiol Infect; 2023 Dec; 29(12):1538-1550. PubMed ID: 37666450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Comprehensive COVID-19 Daily News and Medical Literature Briefing to Inform Health Care and Policy in New Mexico: Implementation Study.
    Jarratt L; Situ J; King RD; Montanez Ramos E; Groves H; Ormesher R; Cossé M; Raboff A; Mahajan A; Thompson J; Ko RF; Paltrow-Krulwich S; Price A; Hurwitz AM; CampBell T; Epler LT; Nguyen F; Wolinsky E; Edwards-Fligner M; Lobo J; Rivera D; Langsjoen J; Sloane L; Hendrix I; Munde EO; Onyango CO; Olewe PK; Anyona SB; Yingling AV; Lauve NR; Kumar P; Stoicu S; Nestsiarovich A; Bologa CG; Oprea TI; Tollestrup K; Myers OB; Anixter M; Perkins DJ; Lambert CG
    JMIR Med Educ; 2022 Feb; 8(1):e23845. PubMed ID: 35142625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Up-to-date role of biologics in the management of respiratory syncytial virus.
    Boyoglu-Barnum S; Tripp RA
    Expert Opin Biol Ther; 2020 Sep; 20(9):1073-1082. PubMed ID: 32264720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The recent progress in RSV vaccine technology.
    Fretzayas A; Papadopoulou A; Kotzia D; Moustaki M
    Recent Pat Antiinfect Drug Discov; 2012 Dec; 7(3):237-41. PubMed ID: 23072645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Respiratory syncytial virus vaccine development.
    Anderson LJ
    Semin Immunol; 2013 Apr; 25(2):160-71. PubMed ID: 23778071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The future of respiratory syncytial virus vaccine development.
    Polack FP; Karron RA
    Pediatr Infect Dis J; 2004 Jan; 23(1 Suppl):S65-73. PubMed ID: 14730272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virus-like particle vaccines containing F or F and G proteins confer protection against respiratory syncytial virus without pulmonary inflammation in cotton rats.
    Hwang HS; Kim KH; Lee Y; Lee YT; Ko EJ; Park S; Lee JS; Lee BC; Kwon YM; Moore ML; Kang SM
    Hum Vaccin Immunother; 2017 May; 13(5):1031-1039. PubMed ID: 28129031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strategic priorities for respiratory syncytial virus (RSV) vaccine development.
    Anderson LJ; Dormitzer PR; Nokes DJ; Rappuoli R; Roca A; Graham BS
    Vaccine; 2013 Apr; 31 Suppl 2(Suppl 2):B209-15. PubMed ID: 23598484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical experience with respiratory syncytial virus vaccines.
    Piedra PA
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S94-9. PubMed ID: 12671459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of mRNA vaccines against respiratory syncytial virus (RSV).
    Qiu X; Xu S; Lu Y; Luo Z; Yan Y; Wang C; Ji J
    Cytokine Growth Factor Rev; 2022 Dec; 68():37-53. PubMed ID: 36280532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The challenges of RSV vaccines. Where do we stand?
    Fretzayas A; Moustaki M
    Recent Pat Antiinfect Drug Discov; 2010 Jun; 5(2):99-107. PubMed ID: 20156180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines.
    Wright PF; Karron RA; Belshe RB; Shi JR; Randolph VB; Collins PL; O'Shea AF; Gruber WC; Murphy BR
    Vaccine; 2007 Oct; 25(42):7372-8. PubMed ID: 17868959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.